Prime Medicine (PRME) Non-Current Deffered Revenue (2024 - 2026)
Prime Medicine (PRME) posted Non-Current Deffered Revenue of $57.8 million for Q1 2026, down 0.61% on a QoQ basis from $58.1 million in Q4 2025, and down 4.75% year-over-year from $60.7 million in Q1 2025.
Prime Medicine (PRME) Non-Current Deffered Revenue (2024 - 2026) Analysis & Trends
Prime Medicine's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $57.8 million for Q1 2026.
- Quarterly Non-Current Deffered Revenue fell 4.75% year-over-year to $57.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.8 million (down 4.75% YoY) and the FY2025 annual result came in at $58.1 million, down 8.05% from the prior year.
- Non-Current Deffered Revenue was $57.8 million for Q1 2026 at Prime Medicine, down from $58.1 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $63.2 million in Q4 2024 and bottomed at $57.8 million in Q1 2026.
- A 3-year average of $60.2 million and a median of $59.8 million in 2025 frame the typical range for Non-Current Deffered Revenue.
- Peak annual rise in Non-Current Deffered Revenue reached 4.61% in 2025, while the deepest fall reached 8.05% in 2025.
- Prime Medicine's Non-Current Deffered Revenue stood at $63.2 million in 2024, then fell by 8.05% to $58.1 million in 2025, then retreated by 0.61% to $57.8 million in 2026.
- Business Quant data shows PRME's Non-Current Deffered Revenue at $57.8 million in Q1 2026, $58.1 million in Q4 2025, and $59.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Prime Medicine | 525.98 Mn | 525.98 Mn | - | 57.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.78 Mn |
| Dec 31, 2025 | 58.13 Mn |
| Sep 30, 2025 | 59.75 Mn |
| Jun 30, 2025 | 59.56 Mn |
| Mar 31, 2025 | 60.66 Mn |
| Dec 31, 2024 | 63.22 Mn |
| Sep 30, 2024 | 62.64 Mn |